Press Releases

89bio to Participate in Upcoming Investor Conferences


SAN FRANCISCO, May 03, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will participate in the following upcoming investor conferences in May:

  • BofA Securities 2022 Healthcare Conference

    Format: Presentation and one-on-one investor meetings
    Date: Tuesday, May 10, 2022
    Presentation Time: 4:20 p.m. EST
  • 2022 RBC Capital Markets Global Healthcare Conference

    Format: Fireside chat and one-on-one investor meetings
    Date: Wednesday, May 18, 2022
    Presentation Time: 10:30 a.m. EST
  • H.C. Wainwright Global Investment Conference

    Format: Presentation and one-on-one investor meetings
    Date: Tuesday, May 24, 2022
    Presentation Time: starting at 7:00 a.m. EST

The webcast of these presentations will be accessible in the investor section of 89bio’s website.

About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco with operations in Herzliya, Israel. For more information, visit or follow the company on LinkedIn.

Investor Contact:
Ryan Martins
Chief Financial Officer


Primary Logo

Source: 89bio, Inc.